drugset / Trial / NCT01600014

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

NCT01600014

Phase 3 Completed 463 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.

Timeline

Start
2012-05
Primary completion
2014-02
Completion
2014-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator ingenol mebutate Small molecule 0.015 % Topical

Indications